Table 1.
SSc patients (n = 15) | |
---|---|
Male/female | 0/15 |
Age (years), median ± IQR | 55 (39–63) |
Cutaneous form: limited/diffuse | 11/4 |
Anti-centromere/anti-topoisomerase I auto-antibodies | 7/6 |
mRSS | 8.5 (3–27) |
Disease duration ≤3 years/>3 years | 5/10 |
Medsger Severity Scale | |
Grade 0–1–2 versus Grade 3–4 | 0–4–5 versus 2–4 |
Pitting scars | 10 |
Digital ulcers | 5 |
Telangiectasias | 10 |
Pulmonary function tests | |
– TLCO (%) | 57 (45–71) |
– TLCO/VA (%) | 67.8 (56.1–76.5) |
– FVC (%) | 100.1 (68.38–111.8) |
Lung fibrosis on HRCT scan | 4 |
Pulmonary arterial fibrosis | 3 |
Quantitative variables are described using median and IQR (first quartile–third quartile).
mRSS, modified Rodnan sclerosis score; DLCO, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; VA, alveolar volume; HRCT, high resolution computed tomography; IQR, interquartile range; SSc, systemic sclerosis.